<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37816710</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>SIRT1 and HSP90&#x3b1; feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas.</ArticleTitle><Pagination><StartPage>667</StartPage><MedlinePgn>667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-023-06186-0</ELocationID><Abstract><AbstractText>Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults, exhibiting highly heterogenous clinical behavior and complex molecular background. In addition to the genetic complexity, different DLBCL subsets exhibit phenotypic features independent of the genetic background. For example, a subset of DLBCLs is distinguished by increased oxidative phosphorylation and unique transcriptional features, including overexpression of certain mitochondrial genes and a molecular chaperone, heat shock protein HSP90&#x3b1; (termed "OxPhos" DLBCLs). In this study, we identified a feed-forward pathogenetic circuit linking HSP90&#x3b1; and SIRT1 in OxPhos DLBCLs. The expression of the inducible HSP90&#x3b1; isoform remains under SIRT1-mediated regulation. SIRT1 knockdown or chemical inhibition reduced HSP90&#x3b1; expression in a mechanism involving HSF1 transcription factor, whereas HSP90 inhibition reduced SIRT1 protein stability, indicating that HSP90 chaperones SIRT1. SIRT1-HSP90&#x3b1; interaction in DLBCL cells was confirmed by co-immunoprecipitation and proximity ligation assay (PLA). The number of SIRT1-HSP90&#x3b1; complexes in PLA was significantly higher in OxPhos- dependent than -independent cells. Importantly, SIRT1-HSP90&#x3b1; interactions in OxPhos DLBCLs markedly increased in mitosis, suggesting a specific role of the complex during this cell cycle phase. RNAi-mediated and chemical inhibition of SIRT1 and/or HSP90 significantly increased the number of cells with chromosome segregation errors (multipolar spindle formation, anaphase bridges and lagging chromosomes). Finally, chemical SIRT1 inhibitors induced dose-dependent cytotoxicity in OxPhos-dependent DLBCL cell lines and synergized with the HSP90 inhibitor. Taken together, our findings define a new OxPhos-DLBCL-specific pathogenetic loop involving SIRT1 and HSP90&#x3b1; that regulates chromosome dynamics during mitosis and may be exploited therapeutically.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bia&#x142;opiotrowicz-Data</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noyszewska-Kania</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jab&#x142;o&#x144;ska</LastName><ForeName>Ewa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sewastianik</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komar</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#x119;bek</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbicz</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojtas</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szyd&#x142;owski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8686-3429</Identifier><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;rniak</LastName><ForeName>Patryk</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juszczy&#x144;ski</LastName><ForeName>Przemys&#x142;aw</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7215-0444</Identifier><AffiliationInfo><Affiliation>Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. pjuszczynski@ihit.waw.pl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TEAM/2011-7/4</GrantID><Agency>Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science)</Agency><Country/></Grant><Grant><GrantID>TEAM/2011-7/4</GrantID><Agency>Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science)</Agency><Country/></Grant><Grant><GrantID>TEAM/2011-7/4</GrantID><Agency>Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37816710</ArticleId><ArticleId IdType="doi">10.1038/s41419-023-06186-0</ArticleId><ArticleId IdType="pii">10.1038/s41419-023-06186-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Cancer Institute. Cancer Stat Facts: NHL &#x2014; Diffuse Large B-Cell Lymphoma (DLBCL). https://seer.cancer.gov/statfacts/html/dlbcl.html</Citation></Reference><Reference><Citation>Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Arnason JE. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020&#x2013;2025. Leuk Lymphoma. 2022;63:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">34510995</ArticleId><ArticleId IdType="doi">10.1080/10428194.2021.1975188</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10676951</ArticleId><ArticleId IdType="doi">10.1038/35000501</ArticleId></ArticleIdList></Reference><Reference><Citation>D. Sandoval-Sus J, Chavez J, Dalia S. A new therapeutic era in GCB and ABC diffuse large B-cell Lymphom a molecular subtypes: a cell of origin-driven review. Curr Cancer Drug Targets. 2016;16:305&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009615666151030102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma&#x2014;treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">24217204</ArticleId><ArticleId IdType="doi">10.1038/nrclinonc.2013.197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-Cell Lymphomas. N Engl J Med. 2008;359:2313&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19038878</ArticleId><ArticleId IdType="pmc">9103713</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0802885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B Cell Lymphoma with therapeutic implications. Cancer Cell. 2020;37:551&#x2013;68.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32289277</ArticleId><ArticleId IdType="pmc">8459709</ArticleId><ArticleId IdType="doi">10.1016/j.ccell.2020.03.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29713087</ArticleId><ArticleId IdType="pmc">6613387</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0016-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell Lymphoma. N Engl J Med. 2018;378:1396&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">29641966</ArticleId><ArticleId IdType="pmc">6010183</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1801445</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti S. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550490</ArticleId><ArticleId IdType="doi">10.1182/blood-2004-07-2947</ArticleId></ArticleIdList></Reference><Reference><Citation>Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell Lymphoma. Cancer Cell. 2012;22:547&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23079663</ArticleId><ArticleId IdType="pmc">3479446</ArticleId><ArticleId IdType="doi">10.1016/j.ccr.2012.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Norberg E, Lako A, Chen PH, Stanley IA, Zhou F, Ficarro SB, et al. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 2017;24:251&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">27768122</ArticleId><ArticleId IdType="doi">10.1038/cdd.2016.116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sewastianik T, Szydlowski M, Jablonska E, Bialopiotrowicz E, Kiliszek P, Gorniak P, et al. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. Oncogene. 2016;35:5989&#x2013;6000.</Citation><ArticleIdList><ArticleId IdType="pubmed">27132507</ArticleId><ArticleId IdType="doi">10.1038/onc.2016.126</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodromou C. Mechanisms of Hsp90 regulation. Biochem J. 2016;473:2439&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27515256</ArticleId><ArticleId IdType="doi">10.1042/BCJ20160005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoter A, El-Sabban M, Naim H. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19:2560.</Citation><ArticleIdList><ArticleId IdType="pubmed">30158430</ArticleId><ArticleId IdType="pmc">6164434</ArticleId><ArticleId IdType="doi">10.3390/ijms19092560</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">23896275</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(13)70169-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong ALC, Ramasamy TS. Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res Rev. 2018;43:64&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29476819</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2018.02.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodina A, Wang T, Yan P, Gomes ED, Dunphy MPS, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538:397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">27706135</ArticleId><ArticleId IdType="pmc">5283383</ArticleId><ArticleId IdType="doi">10.1038/nature19807</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S, Wang T, Araujo TLS, Sharma S, Brodsky JL, Chiosis G. Adapting to stress &#x2014; chaperome networks in cancer. Nat Rev Cancer. 2018;18:562&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">29795326</ArticleId><ArticleId IdType="pmc">6108944</ArticleId><ArticleId IdType="doi">10.1038/s41568-018-0020-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 2009;144:358&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">19036086</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2141.2008.07484.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Investig. 2015;125:4559&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">26529251</ArticleId><ArticleId IdType="pmc">4665772</ArticleId><ArticleId IdType="doi">10.1172/JCI80714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer. 2013;4:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">24019998</ArticleId><ArticleId IdType="pmc">3764475</ArticleId><ArticleId IdType="doi">10.1177/1947601912473826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zeng J, Wu W, Xie S, Yu H, Li G, et al. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Breast Cancer Res. 2019;21:64.</Citation><ArticleIdList><ArticleId IdType="pubmed">31101119</ArticleId><ArticleId IdType="pmc">6525439</ArticleId><ArticleId IdType="doi">10.1186/s13058-019-1150-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousafzai NA, Zhou Q, Xu W, Shi Q, Xu J, Feng L, et al. SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer. Cell Death Dis. 2019;10:363.</Citation><ArticleIdList><ArticleId IdType="pubmed">31043584</ArticleId><ArticleId IdType="pmc">6494911</ArticleId><ArticleId IdType="doi">10.1038/s41419-019-1592-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhao W, Yang JS, Cheng Z, Luo H, Lu Z, et al. Quantitative Acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol Cell Proteom. 2012;11:1048&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M112.019547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1&#x3b1; and SIRT1. Nature. 2005;434:113&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15744310</ArticleId><ArticleId IdType="doi">10.1038/nature03354</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase. Science. 2004;303:2011&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">14976264</ArticleId><ArticleId IdType="doi">10.1126/science.1094637</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The role of Sirtuins in Antioxidant and Redox signaling. Antioxid Redox Signal. 2018;28:643&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891317</ArticleId><ArticleId IdType="pmc">5824489</ArticleId><ArticleId IdType="doi">10.1089/ars.2017.7290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-Cell Lymphoma. Am J Surg Pathol. 2008;32:1523&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18724249</ArticleId><ArticleId IdType="doi">10.1097/PAS.0b013e31816b6478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bia&#x142;opiotrowicz E, G&#xf3;rniak P, Noyszewska&#x2010;Kania M, Pu&#x142;a B, Makuch&#x2010;&#x141;asica H, Nowak G, et al. Microenvironment&#x2010;induced PIM kinases promote CXCR 4&#x2010;triggered MTOR pathway required for chronic lymphocytic leukaemia cell migration. J Cell Mol Med. 2018;22:3548&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">29665227</ArticleId><ArticleId IdType="pmc">6010703</ArticleId><ArticleId IdType="doi">10.1111/jcmm.13632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bia&#x142;opiotrowicz E, Noyszewska-Kania M, Kachamakova-Trojanowska N, &#x141;oboda A, Cybulska M, Grochowska A, et al. Serine biosynthesis pathway supports MYC&#x2013;miR-494&#x2013;EZH2 feed-forward circuit necessary to maintain metabolic and epigenetic reprogramming of Burkitt Lymphoma Cells. Cancers. 2020;12:580.</Citation><ArticleIdList><ArticleId IdType="pubmed">32138178</ArticleId><ArticleId IdType="pmc">7139810</ArticleId><ArticleId IdType="doi">10.3390/cancers12030580</ArticleId></ArticleIdList></Reference><Reference><Citation>Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed&#x2013;Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci. 2007;104:13134&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17670934</ArticleId><ArticleId IdType="pmc">1936978</ArticleId><ArticleId IdType="doi">10.1073/pnas.0706017104</ArticleId></ArticleIdList></Reference><Reference><Citation>Szyd&#x142;owski M, Prochorec-Sobieszek M, Szumera-Cie&#x107;kiewicz A, Derezi&#x144;ska E, Hoser G, Wasilewska D, et al. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017;130:1418&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">28698206</ArticleId><ArticleId IdType="doi">10.1182/blood-2017-01-760702</ArticleId></ArticleIdList></Reference><Reference><Citation>Szyd&#x142;owski M, Garbicz F, Jab&#x142;o&#x144;ska E, G&#xf3;rniak P, Komar D, Pyrzy&#x144;ska B, et al. Inhibition of PIM Kinases in DLBCL Targets MYC transcriptional program and augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. 2021;81:6029&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">34625423</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-1023</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci. 2007;104:3207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17360630</ArticleId><ArticleId IdType="pmc">1805543</ArticleId><ArticleId IdType="doi">10.1073/pnas.0611399104</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelin E, Freeman BC. Lysine Deacetylases regulate the heat shock response including the Age-Associated Impairment of HSF1. J Mol Biol. 2015;427:1644&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">25688804</ArticleId><ArticleId IdType="pmc">4357550</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2015.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerheide SD, Anckar J, Stevens SM, Sistonen L, Morimoto RI. Stress-inducible regulation of heat shock Factor 1 by the Deacetylase SIRT1. Science. 2009;323:1063&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19229036</ArticleId><ArticleId IdType="pmc">3429349</ArticleId><ArticleId IdType="doi">10.1126/science.1165946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, Gil NY, Zhang XH, Chun KH, Fang G, Kim J, et al. Sirt1 regulates microtubule dynamics through negative regulation of Plk1 in mitosis: ROLE OF Sirt1 IN M ITOSIS. J Cell Biochem. 2015;116:1888&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">25737075</ArticleId><ArticleId IdType="doi">10.1002/jcb.25144</ArticleId></ArticleIdList></Reference><Reference><Citation>Silk AD, Zasadil LM, Holland AJ, Vitre B, Cleveland DW, Weaver BA. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proc Natl Acad Sci. 2013;110:E4134&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24133140</ArticleId><ArticleId IdType="pmc">3816416</ArticleId><ArticleId IdType="doi">10.1073/pnas.1317042110</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues-Ferreira S, Nahmias C. From tumorigenesis to cell death: the aneuploidy paradox. Mol Cell Oncol. 2020;7:1709390.</Citation><ArticleIdList><ArticleId IdType="pubmed">32158924</ArticleId><ArticleId IdType="pmc">7051165</ArticleId><ArticleId IdType="doi">10.1080/23723556.2019.1709390</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Vidal MN, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, et al. Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell Lymphomas. Cancer Res. 2021;81:5202&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">34479963</ArticleId><ArticleId IdType="pmc">8530929</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-2734</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2:2039&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">30115641</ArticleId><ArticleId IdType="pmc">6113611</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2018016048</ArticleId></ArticleIdList></Reference><Reference><Citation>Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, L&#xfc;scher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci. 2012;109:E187&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190494</ArticleId><ArticleId IdType="doi">10.1073/pnas.1105304109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6&#x2013;dependent B cell lymphomas. Nat Med. 2009;15:1369&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19966776</ArticleId><ArticleId IdType="pmc">2805915</ArticleId><ArticleId IdType="doi">10.1038/nm.2059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32:606&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402037</ArticleId><ArticleId IdType="doi">10.1038/ng1018</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaziri H, Dessain SK, Eaton EN, Imai SI, Frye RA, Pandita TK, et al. hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase. Cell. 2001;107:149&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672523</ArticleId><ArticleId IdType="doi">10.1016/S0092-8674(01)00527-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Nikolaev AY, Imai Sichiro, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2&#x3b1; promotes cell survival under stress. Cell. 2001;107:137&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672522</ArticleId><ArticleId IdType="doi">10.1016/S0092-8674(01)00524-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasca D, H&#xe4;hnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014;124:121&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">24855208</ArticleId><ArticleId IdType="doi">10.1182/blood-2013-11-538819</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlander SJH, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and Sensitizes Tumor cells to replication stress. J Biol Chem. 2003;278:52572&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570880</ArticleId><ArticleId IdType="doi">10.1074/jbc.M309054200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wang S, Li Y, Yu S, Zhao Y. SIRT1/PGC-1&#x3b1; signaling promotes mitochondrial functional recovery and reduces apoptosis after intracerebral hemorrhage in rats. Front Mol Neurosci. 2018;10:443.</Citation><ArticleIdList><ArticleId IdType="pubmed">29375306</ArticleId><ArticleId IdType="pmc">5767311</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2017.00443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Li X, Zhou L, Wang Y, Shang P. SIRT1: a potential tumour biomarker and therapeutic target. J Drug Target. 2019;27:1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">31056963</ArticleId><ArticleId IdType="doi">10.1080/1061186X.2019.1605519</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Li H, Liu Y, Zhao K, Wei S, Sugarman ET, et al. Targeting HSP90 as a novel therapy for cancer: mechanistic insights and translational relevance. Cells. 2022;11:2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">36139353</ArticleId><ArticleId IdType="pmc">9497295</ArticleId><ArticleId IdType="doi">10.3390/cells11182778</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, et al. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt Lymphoma. Mol Cancer Ther. 2017;16:1779&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28619753</ArticleId><ArticleId IdType="pmc">5587381</ArticleId><ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Peng L, Wang J, Rahhal R, Seto E. Histone Deacetylase SIRT1 Targets Plk2 to regulate centriole duplication. Cell Rep. 2018;25:2851&#x2013;65.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">30517871</ArticleId><ArticleId IdType="pmc">6814291</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Utani K, Fu H, Jang SM, Marks AB, Smith OK, Zhang Y, et al. Phosphorylated SIRT1 associates with replication origins to prevent excess replication initiation and preserve genomic stability. Nucleic Acids Res. 2017;45:7807&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28549174</ArticleId><ArticleId IdType="pmc">5570034</ArticleId><ArticleId IdType="doi">10.1093/nar/gkx468</ArticleId></ArticleIdList></Reference><Reference><Citation>Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15077146</ArticleId><ArticleId IdType="doi">10.1038/sj.onc.1207528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12:385&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527953</ArticleId><ArticleId IdType="doi">10.1038/nrm3115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H, Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis. 2013;4:e603&#x2013;e603.</Citation><ArticleIdList><ArticleId IdType="pubmed">23598415</ArticleId><ArticleId IdType="pmc">3641331</ArticleId><ArticleId IdType="doi">10.1038/cddis.2013.108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3K&#x3b1;/&#x3b4; is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">30322870</ArticleId><ArticleId IdType="pmc">6318426</ArticleId><ArticleId IdType="doi">10.1182/blood-2018-08-872465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">32060403</ArticleId><ArticleId IdType="pmc">7387311</ArticleId><ArticleId IdType="doi">10.1038/s41375-020-0743-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26193343</ArticleId><ArticleId IdType="pmc">8372245</ArticleId><ArticleId IdType="doi">10.1038/nm.3884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, et al. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Lett. 2017;411:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987383</ArticleId><ArticleId IdType="doi">10.1016/j.canlet.2017.09.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharm Ther. 2018;188:140&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, In Vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13:454&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455128</ArticleId><ArticleId IdType="pmc">2742717</ArticleId><ArticleId IdType="doi">10.1016/j.ccr.2008.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotchkina L, Kazyulkin D, Komarov PG, Polinsky A, Andrianova EL, Joshi S, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020;34:1828&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">31896781</ArticleId><ArticleId IdType="pmc">7326709</ArticleId><ArticleId IdType="doi">10.1038/s41375-019-0692-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009;113:3276&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">19196867</ArticleId><ArticleId IdType="doi">10.1182/blood-2008-08-173369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>